Language: BG BG
← Back to results
By invitation only Phase 3 NCT07073014

Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia

Phase 3 – large-scale trial before approval
Conditions: Hypochondroplasia

Sponsor: BioMarin Pharmaceutical

trial.available_in: БГ
Overview
The purpose of this study is to evaluate the long-term safety and efficacy of daily doses of vosoritide in participants with HCH
Who can participate
Inclusion Criteria: * Participants must have completed the Week 52 visit for 111-303 or 111-212 and have open epiphyses as assessed by left hand antero-posterior (AP) X-rays * Parent(s) or guardian(s) must be willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to performance of any study-related procedure * Females ≥ 10 years old or who have begun menses must have a negative pregnancy test at the Baseline visit and be willing to have additional pregnancy tests during the study * If sexually active, participants must be willing to use a highly effective method of contraception while participating in the study * Participants are willing and able to perform all study procedures as physically possible * Parent(s) or caregiver(s) are willing to administer daily injections to the participants and willing to complete the required training Exclusion Criteria: * Permanently discontinued study treatment in the studies 111-303 or 111-212 * Evidence of decreased growth velocity (AGV \< 1.5 cm/year) as assessed over a period of at least 6 months and growth plate closure assessed as per standard of care * Taking or planning to take any prohibited medications * Planned or expected to have limb-lengthening surgery during the study period * Planned or expected bone-related surgery during the study period * Require any investigational agent prior to completion of study period * Have current malignancy, history of malignancy, or currently under work-up for suspected malignancy * Have known hypersensitivity to vosoritide or its excipients * Is pregnant or breastfeeding at Baseline or planning to become pregnant (self or partner) at any time during the study * Concurrent disease or condition that, in the view of the investigator, would interfere with study participation or safety evaluations, for any reason
Locations 9
Australia (1)
Murdoch Children's Research Institute
Parkville , Victoria
Canada (1)
University of Alberta Stollery Children's Hospital
Edmonton , Alberta
France (1)
Hospices Civils de Lyon - Hopital Femme Mere Enfant
Lyon
Germany (1)
Uniklinik Koln
Cologne
Italy (1)
Instituto Giannina Gaslini
Genoa
Japan (1)
Osaka University Hosptial
Osaka
Spain (1)
Vithas Hospital San Jose
Vitoria-Gasteiz
United Kingdom (1)
Great Ormond Street Hospital for Children NHS Foundation Trust
London
United States (1)
Nemours Children's Hospital, Delaware (Alfred I. Dupont Hospital for Children)
Wilmington , Delaware
Technical details
Status
By invitation only
Phase
Phase 3
Study type
INTERVENTIONAL
Sex
Male and female
Healthy volunteers
No
Start date
20.06.2025
Completion date
01.12.2040
Registry ID
NCT07073014
Source
anzctr
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.